CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved. CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved.

Baby Bunting share price: is the stock a buy?

We unpack Baby Bunting's latest H1 results as well as look at what one top broker is currently saying about the stock.

Touting strong growth in a niche space, Baby Bunting (ASX: BBN) – a self-described one stop baby shop – has seen its share price rise more than 60% in the last 12-months.

Baby Bunting share price: interim results in focus

The release of the company’s interim results last week gave investors insight into how the company performed during the last six months of CY20 – and maybe most importantly: whether or not that ~60% run-up was justified.

Indeed, though the market first responded negatively – with the stock being bid down more than 10% following the H1 release – the share price has since stabilised.

Do you own Baby Bunting shares? You can hedge your downside risk by trading CFDs now.

Looking at these results, on the top-line, the company reported sales of $186.4 million – representing 8% growth on a pcp basis.

On the bottom-line, the company reported pro forma earnings (EBITDA) of $14.3 million (+21% on a pcp basis) and profits (NPAT) of $4.8 million. Margins also improved during the half, with gross profit margins hitting 36.9%.

The company further expects FY20 gross margins to come in even stronger: at 37.0%.

This margin outlook, said the company 'is an outcome of working with our supplier partners on range improvements, further improvements in trading terms, optimising supply chain opportunities and increases in direct import volumes.'

One key negative that stood out however as part of these results was commentary surrounding the potential impact of the Coronavirus.

Here it was noted that because 'Baby Bunting sources products, either directly or through distributors, from China. The effect on Baby Bunting arising from the coronavirus outbreak in China cannot yet be readily determined.'

The company did however reassure investor thats it had ‘sufficient’ stock on hand – suggesting there would be no inventory short-falls just yet.

The analyst view

In response to the H1, Citi reiterated their 'buy' rating and upgraded their share price target to $4.05 from $3.90 on BBN.

With Baby Bunting (ASX: BBN) currently trading at $3.58 per share, that price target would imply upside of ~13%.

The investment bank expects Baby Bunting to report FY20 sales of 403.5 million against earnings (Core NPAT) of $21.0 million.

However Citi analysts did flag that their NPAT guidance 'does not account for coronavirus disruption.'

'That said we see Baby Bunting as less exposed to this risk compared to other retailers given the company's elevated stock position following weaker than expected 1H20 sales combined with the fact that its suppliers also hold stock in Australia,’ Citi analysts also said.

Of the four brokers covering the stock, all of them rate Baby Bunting a ‘buy’, according to Bloomberg Data.

Practise trading Australian stocks with an IG demo account now.


The information on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG Bank S.A. accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer.

Act on share opportunities today

Go long or short on thousands of international stocks with CFDs.

  • Get full exposure for a comparatively small deposit
  • Trade on spreads from just 0.1%
  • Get greater order book visibility with direct market access

See opportunity on a stock?

Try a risk-free trade in your demo account, and see whether you’re on to something.

  • Log in to your demo
  • Take your position
  • See whether your hunch pays off

See opportunity on a stock?

Don’t miss your chance – upgrade to a live account to take advantage.

  • Trade a huge range of popular stocks
  • Analyse and deal seamlessly on fast, intuitive charts
  • See and react to breaking news in-platform

See opportunity on a stock?

Don’t miss your chance. Log in to take your position.

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
liveprices.javascriptrequired
liveprices.javascriptrequired
liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.